MILES-02: Study of Chemotherapy Treatment and Toxicity in Elderly Patients With Advanced Non Small Cell Lung Cancer
- Sponsor
- National Cancer Institute, Naples
- Study ID
- NCT00401492
- Phase
- PHASE2
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 70 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- gemcitabine prolonged continuous infusion — DRUG
- cisplatin — DRUG
- vinorelbine — DRUG
Study Details
The main purpose of this study is to describe activity and toxicity of single-agent gemcitabine given as prolonged infusion, and of two 2-drug combinations containing cisplatin (cisplatin + vinorelbine, and cisplatin + gemcitabine) in the treatment of elderly patients with advanced non small cell lung cancer
Key Dates
- Start date
- Jun 30, 2002
- Status verified
- Jul 2012
- Primary completion
- Dec 31, 2006
- Completion
- Apr 30, 2007
Study Design
- Enrollment
- 159 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Primary Outcome Measure
Activity and toxicity of monochemotherapy with gemcitabine as prolonged infusion
Related Studies
- The Effect of Beta-glucan in Non-Small Cell Lung CancerRecruiting · University of Louisville · Louisville, Kentucky
- Dabrafenib and/or Trametinib Rollover StudyPHASE4 · Recruiting · Novartis Pharmaceuticals · Scottsdale, Arizona
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama
- Study of NEO-201 in Solid Tumors Expansion CohortsPHASE1/PHASE2 · Recruiting · Precision Biologics, Inc · Bethesda, Maryland